Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Förbättrad dermatologisk vård för att minska utslag och paronykier i epidermal tillväxtfaktorreceptor (EGRF)-muterad icke-småcellig lungcancer (NSCLC) behandlad första linjen med Amivantamab Plus Lazertinib (COCOON)

2 november 2026 uppdaterad av: Janssen Research & Development, LLC

En fas 2, öppen, randomiserad studie som utvärderar effekten av förbättrad kontra standard dermatologisk behandling på utvalda dermatologiska biverkningar bland patienter med lokalt avancerad eller metastaserad EGFR-muterad NSCLC som behandlats i första linjen med Amivantamab + Lazertinib

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

305

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Buenos Aires, Argentina, C1199
        • Hospital Italiano de Buenos Aires
      • CABA, Argentina, C1122
        • IADT Instituto Argentino de Diagnostico y Tratamiento
      • Capital Federal, Argentina, C1017
        • Centro Medico Austral
      • La Plata, Argentina, B1900AXI
        • Hospital Italiano de La Plata
      • Mar del Plata, Argentina, B7602
        • Hospital Privado de la Comunidad
      • Belo Horizonte, Brasilien, 30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Belém, Brasilien, 66.073-005
        • CTO Centro De Tratamento Oncologico LTDA
      • Curitiba, Brasilien, 81520-060
        • Liga Paranaense de Combate ao Cancer
      • Jaú, Brasilien, 17.210-080
        • Fundacao Doutor Amaral Carvalho
      • Porto Alegre, Brasilien, 91350 200
        • Hospital Nossa Senhora da Conceicao S A
      • Salvador, Brasilien, 40170 070
        • Nucleo de Oncologia da Bahia Oncoclinicas
      • Santa Cruz do Sul, Brasilien, 96835-100
        • Hospital Ana Nery Santa Cruz do Sul
      • São Paulo, Brasilien, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasilien, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • Taubaté, Brasilien, 12030-200
        • Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate
      • Vitória, Brasilien, 29043-260
        • Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
      • Marseille, Frankrike, 13915
        • Hopital Nord
      • Nice, Frankrike, 06001
        • Hopital PASTEUR
      • Paris, Frankrike, 75005
        • Institut Curie
    • Arizona
      • Chandler, Arizona, Förenta staterna, 85224
        • Ironwood Cancer and Research Center
    • California
      • Duarte, California, Förenta staterna, 91010
        • City of Hope
      • Fullerton, California, Förenta staterna, 92835
        • Providence Fullerton
      • Glendale, California, Förenta staterna, 91204
        • Los Angeles Cancer Network
      • Huntington Beach, California, Förenta staterna, 92648
        • City of Hope Seacliff
      • Irvine, California, Förenta staterna, 92618
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Long Beach, California, Förenta staterna, 90813
        • City of Hope Long Beach Elm
      • Los Alamitos, California, Förenta staterna, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Förenta staterna, 90033
        • Keck Hospital of USC
      • Newport Beach, California, Förenta staterna, 92663
        • USC Norris Oncology Hematology Newport Beach
      • Oakland, California, Förenta staterna, 94611
        • Kaiser Permanente Oakland Medical Center
      • Roseville, California, Förenta staterna, 95661
        • Kaiser Permanente Roseville Medical Center
      • San Francisco, California, Förenta staterna, 94115
        • Kaiser Permanente San Francisco Medical Center
      • Santa Clara, California, Förenta staterna, 95051
        • Kaiser Permanente Santa Clara Medical Center
      • South Pasadena, California, Förenta staterna, 91030
        • City of Hope South Pasadena
      • Vallejo, California, Förenta staterna, 94589
        • Kaiser Permanente Northern California
      • Walnut Creek, California, Förenta staterna, 94596
        • Kaiser Permanente Walnut Creek Medical Center
    • Georgia
      • Athens, Georgia, Förenta staterna, 30607
        • University Cancer & Blood Center
    • Illinois
      • Hinsdale, Illinois, Förenta staterna, 60521
        • Hope and Healing Care
    • Missouri
      • Springfield, Missouri, Förenta staterna, 65807
        • Oncology Hematology Associates
    • Nevada
      • Reno, Nevada, Förenta staterna, 89502
        • Renown Health Medical Oncology
    • New Jersey
      • Flemington, New Jersey, Förenta staterna, 08822
        • Hunterdon Hematology Oncology
    • New York
      • Westbury, New York, Förenta staterna, 11590
        • Clinical Research Alliance Inc
    • North Carolina
      • Wilson, North Carolina, Förenta staterna, 27893
        • Regional Medical Oncology Center
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Virginia Cancer Specialists
    • Washington
      • Renton, Washington, Förenta staterna, 98055
        • Valley Medical Center
    • Wisconsin
      • West Salem, Wisconsin, Förenta staterna, 54669
        • Gundersen Health System
      • Changzhou, Kina, 213004
        • Changzhou No 2 Peoples Hospital
      • Chengdoucun, Kina, 610041
        • West China Hospital
      • Chengdu, Kina, 610041
        • Sichuan Cancer Hospital
      • Guangzhou, Kina, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou, Kina, 310003
        • The First Affiliated Hospital Zhejiang University School of Medicine
      • Harbin, Kina, 150040
        • Harbin medical university cancer hospital
      • Huizhou, Kina, 516001
        • Huizhou Municipal Central Hospital
      • Nanjing, Kina, 210000
        • Zhongda Hospital Southeast University
      • Shanghai, Kina, 200032
        • Fudan University Shanghai Cancer Center
      • Xi'an, Kina, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Zhengzhou, Kina, 450008
        • Henan Cancer Hospital
      • George Town, Malaysia, 10450
        • Hospital Pulau Pinang
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Kuantan, Malaysia, 25100
        • Hospital Tengku Ampuan Afzan
      • Kuching, Malaysia, 93586
        • Hospital Umum Sarawak
      • A Coruña, Spanien, 15006
        • Hosp Univ A Coruna
      • Alicante, Spanien, 03010
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Spanien, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, Spanien, 08035
        • Hosp Univ Vall D Hebron
      • Jaén, Spanien, 23007
        • Hosp. Univ. de Jaen
      • Lugo, Spanien, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, Spanien, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Málaga, Spanien, 29010
        • Hosp Regional Univ de Malaga
      • Seville, Spanien, 41014
        • Hosp. Ntra. Sra. de Valme
      • Cheongju-si, Sydkorea, 28644
        • Chungbuk National University Hospital
      • Incheon, Sydkorea, 21565
        • Gachon University Gil Medical Center
      • Seoul, Sydkorea, 03722
        • Severance Hospital Yonsei University Health System
      • Hsinchu, Taiwan, 30059
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City, Taiwan, 833
        • Chang Gung Memorial Hospital
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Taoyuan City, Taiwan, 333
        • Linkou Chang Gung Memorial Hospital
      • Adana, Turkiet (Türkiye), 1060
        • Adana City Hospital
      • Ankara, Turkiet (Türkiye), 06560
        • Gazi University Hospital
      • Ankara, Turkiet (Türkiye), 06010
        • Gulhane Training and Research Hospital
      • Ankara, Turkiet (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Istanbul, Turkiet (Türkiye), 34147
        • Bakirkoy Training and Research Hospital
      • Istanbul, Turkiet (Türkiye), 34295
        • I A U VM Medical Park Florya Hastanesi
      • Izmir, Turkiet (Türkiye), 35100
        • Ege University Medical Faculty
      • Samsun, Turkiet (Türkiye), 55420
        • Ondokuz Mayis University
      • Aachen, Tyskland, 52074
        • Universitaetsklinikum der RWTH Aachen
      • Essen, Tyskland, 45136
        • Kliniken Essen-Mitte
      • Giessen, Tyskland, 35392
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Heidelberg, Tyskland, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Kassel, Tyskland, 34125
        • Klinikum Kassel GmbH
      • Kiel, Tyskland, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
  • Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
  • A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
  • Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
  • Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care [SoC]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)

Exclusion Criteria:

  • History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
  • Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
  • Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
  • Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm A: Enhanced Dermatologic Management

Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1).

Amivantamab will be administered.

Andra namn:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Aktiv komparator: Arm B: Standard-of-Care Dermatologic Management

Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm.

Amivantamab will be administered.

Andra namn:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Experimentell: Sub-study: Cohort A: Ruxolitinib

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

Andra namn:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Experimentell: Sub-study: Cohort B: Tacrolimus

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

Andra namn:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Tacrolimus will be used as topical application to the affected skin area.

Experimentell: Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Amivantamab will be administered as SC injection.

Andra namn:
  • JNJ-61186372

Zinc gluconate tablet will be administered.

Propranolol tablet will be administered.

Timolol will be used to the affected skin area.

Clobetasol shampoo will be used on the scalp.

Experimentell: Amivantamab SC Expansion Cohort: Modified Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

Andra namn:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Amivantamab will be administered as SC injection.

Andra namn:
  • JNJ-61186372

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
Tidsram: Up to 12 weeks after initiation of anticancer treatment

Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0
Tidsram: Up to 12 weeks after initiation of anticancer treatment

Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 weeks after initiation of anticancer treatment
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0
Tidsram: Up to 6 months after initiation of anticancer treatment

Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Grade >= 2 DAEI Per Participants
Tidsram: Up to 12 months

Number of grade >= 2 DAEI per participants will be reported.

Up to 12 months
Time to First Occurrence of Grade >=2 DAEI
Tidsram: Up to 12 months

Time to first occurrence of Grade >=2 DAEI will be reported.

Up to 12 months
Time to Resolution of Grade >= 2 DAEI
Tidsram: Up to 12 months

Time to resolution of Grade >= 2 DAEI will be reported.

Up to 12 months
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0
Tidsram: Up to 6 months after initiation of anticancer treatment

Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0
Tidsram: Up to 12 months after initiation of anticancer treatment

Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 months after initiation of anticancer treatment
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months
Tidsram: Baseline, up to Month 12

Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions.

Baseline, up to Month 12
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months
Tidsram: Baseline, up to Month 12

Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale.

Baseline, up to Month 12
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months
Tidsram: Baseline, up to Month 12

Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline, up to Month 12
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only)
Tidsram: Baseline, up to Month 12

The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]).

Baseline, up to Month 12
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs
Tidsram: Up to 12 months

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported.

Up to 12 months
Relative Dose Intensity (RDI) of Anticancer Treatment
Tidsram: Up to 12 months

Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose.

Up to 12 months
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
Tidsram: Up to 12 months

Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
Tidsram: Up to 12 months

Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Progression Free Survival (PFS)
Tidsram: Up to 12 months

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first.

Up to 12 months
Overall Response Rate (ORR)
Tidsram: Up to 12 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator.

Up to 12 months
Duration of Response (DoR)
Tidsram: Up to 12 months

DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria.

Up to 12 months
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment
Tidsram: Up to 12 weeks after initiation of anticancer treatment

Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention
Tidsram: Up to 12 months

Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention
Tidsram: Up to 12 months

Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event
Tidsram: Up to 12 weeks

Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported.

Up to 12 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

16 februari 2024

Primärt slutförande (Beräknad)

31 maj 2027

Avslutad studie (Beräknad)

30 juni 2030

Studieregistreringsdatum

Först inskickad

2 november 2023

Först inskickad som uppfyllde QC-kriterierna

2 november 2023

Första postat (Faktisk)

7 november 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera